



10745 Westside Way, Suite 200

Alpharetta, GA 30009

Tel: +1 (844) 884 5367

Email: info@vtivision.com

www.vtvision.com

www.vtvisioninvestors.com (for investors)

ASX Announcement

Visioneering Technologies, Inc. Reports Q3 2018 Results and First Million-Dollar Revenue Quarter

Highlights for the quarter ended 30 September 2018

- Quarterly net revenue and Shipments to ECPs both exceeded US\$1.0 million (75% and 48% growth QoQ, respectively)
- Achieved first sales in Australia and the first sales outside the US (OUS)
- Signed first OUS distribution agreements, covering Australia, New Zealand and the Nordics
- Successful private placement and SPP, raising US\$6.3 million net of transaction costs
- Reduced net cash used in operating activities by 35% QoQ to US\$3.3 million
- Cash and cash equivalents at end of quarter of US\$10.1 million

Atlanta, Georgia, 11 October 2018 (12 October 2018 AEST): Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, has released today its Appendix 4C – Quarterly Cash Flow for the period ended 30 September 2018 (3Q18).

Quarterly net revenue and Shipments to ECPs (Eye Care Professionals) were:

(US\$ in 000's, unaudited)	2Q17	3Q17	4Q17	1Q18	2Q18	3Q18
Net Revenue	\$182	\$354	\$396	\$555	\$607	\$1,063
Shipments to ECPs*	\$194	\$277	\$326	\$489	\$683	\$1,014
Growth in Shipments to ECPs	56%	43%	18%	50%	40%	48%

*Shipments to ECPs represents the gross revenue equivalent of lenses shipped to ECPs, net of fulfillment fees.

3Q18 net revenue was \$1.1 million, an increase of 75% over 2Q18 and 200% over 3Q17. Shipments to ECPs were \$1.0 million, an increase of 48% over 2Q18 and 266% over 3Q17. During the quarter, VTI received its first revenue from outside the United States from its first two Australia-based ECPs. The Company generated these increases through recent introductions of new products, increasing awareness of the VTI brand, and the benefit of in-market learning and experience over the past few quarters.

"VTI achieved its first US million-dollar quarter, in terms of both net revenue and Shipments to ECPs," said Stephen Snowdy, PhD, CEO of VTI. "In this quarter alone, we exceeded our net revenue from all of 2017, and saw net revenue in the quarter that was comparable to the first half of 2018. We believe these results are a manifestation of the groundwork we have been laying in prior quarters, and the growing awareness of the unique benefits and quality of performance of our NaturalVue lenses."

In the third quarter of 2018, VTI also signed distribution agreements for Australia and New Zealand, and for the Nordic countries of Sweden, Norway, Finland, Denmark and Iceland. VTI expects to begin selling products to the new ANZ and Nordic distributors in the fourth quarter of 2018.

In addition to the strong revenue performance, VTI strengthened its cash position. The Company successfully completed a private placement and a Security Purchase Plan during the quarter, raising US\$6.3 million after transaction expenses. VTI also reduced its net cash used in operating activities by 35%, from US\$5.1 million in 2Q18 to US\$3.3 million in 3Q18, primarily by generating higher revenue and related cash receipts in 3Q18 and incurring lower costs relating to product launches in 3Q18 compared to 2Q18. The Company finished the quarter with US\$10.1 million in cash and cash equivalents, an increase of US\$3.0 million from US\$7.1 million at the end of 2Q18.

Snowdy continued, “We are also excited by the opportunities we have unlocked outside the US by signing distribution agreements in ANZ and Europe, and recognizing our first international revenues. During this quarter, we also completed an equity financing and lowered our net outflow of cash. Overall, we are very pleased with our quarterly and year-to-date performance, and we are proud of the entire team at VTI.”

Investor Conference Call

Investors are invited to join a conference call on Monday 15 October at 9am AEST (Sunday 6pm US EDT) hosted by Visioneering’s CEO, Stephen Snowdy.

To pre-register for the call please use this link:

<https://services.choruscall.com.au/diamondpass/vtivation-684253-invite.html>

You will receive a calendar notification with dial in details and a PIN for fast track access to the call. Alternatively you can dial in using the details below at the scheduled call start time.

Conference ID: 684 253

Participant dial in numbers

Australia Toll Free:	1 800 558 698
Alternate Australia Toll Free:	1 800 809 971
Australia Local:	02 9007 3187
Canada:	1855 8811 339
Japan:	0053 116 1281
New Zealand Toll Free:	0800 453 055
United Kingdom:	0800 051 8245
United States:	(855) 881 1339
US Local (New York):	(914) 202 3258
US Local (Los Angeles):	(909) 235 4020
US Local (Chicago):	(815) 373 2080

For more information, please contact:

Company	Investor and media relations
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: ssnowdy@vtivision.com	Lauren Nowak WE Buchan Tel: +61 (3) 9866 4722 Email: lnowak@buchanwe.com.au

About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue® Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI's Neurofocus Optics® technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and received the CE Mark, as well as TGA and MedSafe approval in early 2018. VTI commenced its US market expansion for NaturalVue MF contact lenses in 2017, and has broadened its reach into international markets in 2018. VTI also sells and plans additional contact lens products.

Foreign ownership restrictions:

VTI's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

MKT-VTI-ASX5

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Visioneering Technologies, Inc.

ABN

616 156 248

Quarter ended ("current quarter")

September 30, 2018

Consolidated statement of cash flows		Current quarter US\$'000	Year to date (9 months) US\$'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	1,147	2,358
1.2	Payments for		
	(a) research and development	(387)	(1,195)
	(b) product manufacturing and operating costs	(801)	(3,591)
	(c) advertising and marketing	(365)	(1,248)
	(d) leased assets	-	-
	(e) staff costs	(2,170)	(6,772)
	(f) administration and corporate costs	(772)	(2,428)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	29	113
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	(3,319)	(12,763)
2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) property, plant and equipment	-	(1)
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	(7)	(47)
	(e) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter US\$'000	Year to date (9 months) US\$'000
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(7)	(48)
3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	6,736	6,736
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	(410)	(410)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	6,326	6,326
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	7,099	16,584
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,319)	(12,763)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(7)	(48)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	6,326	6,326
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of quarter	10,099	10,099

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter US\$'000	Previous quarter US\$'000
5.1	Bank balances	250	250
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (#)	9,849	6,849
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	10,099	7,099

U.S. Treasury bills, notes, and other high-quality, short term securities that are issued or guaranteed by the U.S. government or by U.S. government agencies.

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter US\$'000
67
-

--

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

Current quarter US\$'000
-
-

--

8. Financing facilities available

Add notes as necessary for an understanding of the position

- 8.1 Loan facilities
8.2 Credit standby arrangements
8.3 Other (please specify)

Total facility amount at quarter end US\$'000	Amount drawn at quarter end US\$'000
-	-
-	-
-	-

- 8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

--

9. Estimated cash outflows for next quarter

US\$'000

9.1	Research and development	359
9.2	Product manufacturing and operating costs	217
9.3	Advertising and marketing	399
9.4	Leased assets	-
9.5	Staff costs	2,278
9.6	Administration and corporate costs	626
9.7	Other (provide details if material)	-
9.8	Total estimated cash outflows	3,879

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)

Acquisitions


Disposals

10.1	Name of entity	N/A	N/A
10.2	Place of incorporation or registration		
10.3	Consideration for acquisition or disposal		
10.4	Total net assets		
10.5	Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
2 This statement gives a true and fair view of the matters disclosed.

Sign here:

.....
(Director/Company secretary)

Date:12 October 2018.....

Print name:Stephen Snowdy.....

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.